Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	12.74	12.74	13.27	12.63	18.63	17.93
Revenue Growth (YoY)	-4.05%	-4.05%	5.10%	-32.21%	3.91%	-5.49%
Cost of Revenue	7.99	7.99	8.8	8.64	12.07	9.81
Gross Profit	4.75	4.75	4.48	3.99	6.56	8.12
Selling, General & Admin	7.58	7.58	8.84	9.76	9.45	14.17
Research & Development	1.87	1.87	0.21	0.13	0.56	1.34
Other Operating Expenses	0	0	0	-0.15	-0.14	-3.57
Operating Expenses	9.45	9.45	9.05	9.73	9.87	11.94
Operating Income	-4.7	-4.7	-4.57	-5.74	-3.31	-3.82
Interest Expense / Income	0	0	0	0.01	-0	0.02
Other Expense / Income	0.33	0.33	0.61	-0.33	-0.07	-0.56
Pretax Income	-5.03	-5.03	-5.18	-5.42	-3.24	-3.28
Income Tax	-0.2	-0.2	-0.03	-0.33	0.71	0.03
Net Income	-4.84	-4.84	-5.15	-5.09	-3.95	-3.31
Shares Outstanding (Basic)	9	9	3	3	2	1
Shares Outstanding (Diluted)	9	9	3	3	2	1
Shares Change	167.83%	167.83%	27.93%	32.92%	35.14%	59.85%
EPS (Basic)	-0.53	-0.53	-1.52	-1.92	-1.97	-2.24
EPS (Diluted)	-0.53	-0.53	-1.52	-1.92	-1.97	-2.24
Free Cash Flow	-2.42	-2.42	-6.42	-4.39	-3.56	-4.8
Free Cash Flow Per Share	-0.27	-0.27	-1.89	-1.65	-1.78	-3.25
Gross Margin	37.26%	37.26%	33.73%	31.62%	35.21%	45.30%
Operating Margin	-36.91%	-36.91%	-34.43%	-45.43%	-17.78%	-21.30%
Profit Margin	-37.97%	-37.97%	-38.81%	-40.28%	-21.20%	-18.45%
Free Cash Flow Margin	-18.96%	-18.96%	-48.38%	-34.72%	-19.09%	-26.76%
EBITDA	-4.86	-4.86	-5.06	-5.22	-3.01	-2.95
EBITDA Margin	-38.12%	-38.12%	-38.12%	-41.35%	-16.18%	-16.46%
Depreciation & Amortization	0.18	0.18	0.13	0.19	0.23	0.31
EBIT	-5.03	-5.03	-5.18	-5.41	-3.24	-3.26
EBIT Margin	-39.51%	-39.51%	-39.06%	-42.83%	-17.40%	-18.20%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).